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Borna disease (BD), caused by the neurotropic RNA virus, Borna Disease virus, is an aﬄiction ranging from asymptomatic to
fatal meningoencephalitis across naturally and experimentally infected warmblooded (mammalian and bird) species. More than
100 years after the ﬁrst clinical descriptions of Borna disease in horses and studies beginning in the 1980’s linking Borna disease
virus to human neuropsychiatric diseases, experimentally infected rodents have been used as models for examining behavioral,
neuropharmacological, and neurochemical responses to viral challenge at diﬀerent stages of life. These studies have contributed to
understanding the role of CNS viral injury in vulnerability to behavioral, developmental, epileptic, and neurodegenerative diseases
and aided evaluation of the proposed and still controversial links to human disease.
1.Introduction
Whydoweneedanimalmodelsforneurotropicviralstudies?
Some day, human functional neuroimaging may provide
consistent reliable experimentation in our species, or genetic
biomarkers may have predictive validity for disease course
or vulnerability. However, until detailed neuroanatomical,
molecular and cellular changes needed to understand CNS
viral pathogenesis become accessible by these methods,
animal models will be needed to evaluate agent-speciﬁc and
general principles of neurovirology.
In 1985, when Borna disease virus (BDV) was proposed
as an etiologic agent of bipolar aﬀective disorder based on
detection of BDV antibodies in serum of 1.6% (16/979) of
psychiatric patients [1], work on BDV infection of small
laboratory animals was well underway. By 1988, when
the virus had been implicated in aﬀective disorders and
schizophrenia [2], experimental work was expanding and
becoming increasingly reliant on in vivo animal studies.
Small laboratory animals could be readily infected and
demonstrate signs of disease in a short, predictable time
frame. Rats and mice oﬀered speciﬁc advantages, because
rodent nervous systems had been extensively mapped. In
time, the use of select animal models would elucidate many
neurobiological substrates of viral injury and disrupted
behavior,andaidintestingthehypothesisthatBDVmaybea
cause of human neuropsychiatric diseases. The experimental
history of use of behaving animals as subjects in Borna
disease virus research is the subject of this review.
2. History of Borna DiseaseVirus
Borna disease (BD) was a sporadic, epidemic encephalitis of
horses and sheep in 18th and 19th century Central Europe,
described as hitzige Kopfkrankheit “heated head disease” of
cavalry horses in 1885 in the town of Borna in Saxony,
Germany [3–5]. In horses, a variety of syndromes were rec-
ognized, including excitability and hyperactivity, movement
and posture disorders [4, 6, 7]. Although typically fatal, there
wassuﬃcientvariability in expression and progression of BD
to imply that host, age, virus strain, and mode of infection
may inﬂuence disease. Whether clinical features vary with
host attributes or immune status would be followed up by
veterinary pathologists and virologists.
WorkinexperimentalBDVinfection,beguninratsinthe
1960’s[8]acceleratedinthe1970’sand1980’swithmorerats,
as well as mice, rabbits, tree shrews, and rhesus monkeys.
Borna disease had distinct characteristics across species [6].
For example, rats showed hyperactive movements, behavior
disorders, and poor maze learning [9–12] while most strains2 Interdisciplinary Perspectives on Infectious Diseases
of mice were asymptomatic [13]. Rhesus monkeys showed
hyperactivity, aggression, disinhibited behaviors then apathy
[14], and tree shrews, a lower primate, displayed abnormal
sexualandsocialbehaviors[15].ForstudyofBDV,smalllab-
oratoryanimalswerebecominganexperimentallyaccessible,
less expensive, and reproducible alternative to post mortem
study of large domestic farm animals.
Early experimental animal work used Strain V, Giessen
strain He/80 (Hessen/80) or ﬁeld strains: wild-type virus
from brain suspensions from horses that had recently died.
Strain V originated from a naturally infected horse in 1929.
Strain V was ﬁrst prepared as wild-type virus in horse brain
homogenate, then developed as a rabbit-adapted BD virus
[3] and later rat- or mouse-adapted by serial brain passage
in newborn rats or mice [11]. He/80, another horse-derived
BDV isolate, was prepared ﬁrst in rabbits by intracerebral
inoculation and cultures of fetal rabbit brain, and then rat-
or mouse-adapted by serial brain passage in newborns of the
intended experimental species [10].
Not long after reports of an expanding natural host
range [5] and demonstration of a broad experimental host
range for BDV, came reports of the virus’ association with
human neuropsychiatric diseases. From the 1985 proposal
that Borna disease virus was an etiologic agent of manic-
depressive disorders [1], a large number of reports linking
Bornadiseasevirustohumanaﬀectivedisorders,schizophre-
nia, CNS inﬂammatory and degenerative diseases followed.
Theassociationsandcontroversiesregardinghumandiseases
are discussed in several comprehensive reviews [16, 17]. The
earlyassociationswithhumandiseasedrovethedevelopment
and further expansion of BD animal model systems and
testing paradigms. Animal models could be used to address
veryspeciﬁcquestions,whetherBornadiseasevirusisacause
or cofactor in human neuropsychiatric disease, for example,
based on development of serologic, detection and transmis-
sion criteria, or recognition of biomarkers of disease.
In addition, the animal models could be used to advance
more abstract lines of investigation: whether neurotropic
viruses would elucidate aspects of nervous system function
and plasticity. Because BDV was associated with psychiatric
diseasesofmaninthelate1980’s,diseaseswithnounderlying
histopathology by standard microscopy techniques of the
time, investigators began to consider whether infection by
a non-lytic, slow-growing, neurotropic virus itself could
render CNS pharmacologic and neurochemical changes. The
background and experimental paradigms for ascertaining
the validity of virus-induced neurotransmitter eﬀects were
already in place, due to widening knowledge of the func-
tional anatomy, neuropharmacology and neurochemistry of
prefrontal, motor, reward, and limbic circuits rendered by
animal models developed during the 1980’s and 1990’s [18].
Animalmodelsforaddictionandpsychiatryweresomeofthe
most robust in neurobiology. The recording of movement,
behavior or cognitive disorders in experimentally infected
rodents [9–12, 19, 20] and primates [14, 15], led to the study
of these syndromes in the context of speciﬁc circuit, neu-
rotransmitter or pharmacologic paradigms. In other words,
a neural (neurotransmitter) systems approach to solving a
problem in viral pathogenesis, such as how BDV causes
movement and behavior disorders in aﬀected species, devel-
oped. The approach would rely heavily on behavioral testing.
3. Adolescent-Infected Rats
In experimentally-infected adolescent rats, BDV caused a
multiphasic syndrome characterized by hyperactivity, dysk-
inesias, stereotypies, excitability, stimulus sensitivity, self-
mutilation, followed by dystonia, ataxia, paresis, seizures and
premature senescence [9, 19]. Interestingly, the early stage of
disease resembled psychostimulant sensitization or overdose
in rats. Looking like a syndrome of apparent dopamine
(DA) excess or sensitivity, Borna disease of rats could be
probed with speciﬁc pharmacologic agents to establish the
neuropharmacological basis for the behaviors. Behavioral
supersensitivity to the dopaminergic psychostimulants d-
amphetamine [19] and cocaine [21] was shown using pho-
tocell cages for automated activity recordings and behavior
rating scales developed for the study of amphetamine dose-
response curves in rats.
Demonstration of psychostimulant sensitivity was fol-
lowed by study of pre- and postsynaptic eﬀects of infection
in dopaminergic extrapyramidal motor and reward circuits.
In the nigrostriatal system, partial DA deaﬀerentation and
compensatoryhyperactivityinsurvivingstriatalnervetermi-
nals [19] along with tyrosine hydroxylase (TH) hyperphos-
phorylation and TH metabolic hyperactivity in nigrostriatal
projections [22] were bases for locomotor hyperacitivity
and stimulant sensitivity. Reduced dopamine D2 and D3
receptors but preserved D1 receptor numbers in striatum
(caudateputamenandnucleusaccumbens)[19,23]underlay
the BD rat’s motor dyskinesias and later stage dystonia.
Reduced D2 striatal receptors and the reduced indirect
striatal pathway throughput that results, is the primary
pathologyalsoofHuntington’sdisease,thechoreicsyndrome
of man. Hyperactivity and fearless, disinhibited behaviors
were associated with metabolic changes in the prefrontal
DA circuits [24], while cognitive decline was linked to fore-
brain cholinergic loss [25, 26], a pathology of Alzheimer’s
disease.
The neuropharmacologic and neurochemical changes
supported the possibility of a link between BDV and human
neuropsychiatric syndromes with dopaminergic substrates,
such as schizophrenia, extrapyramidal (movement) disor-
ders, addictions, or cholinergic substrates, such as dementia.
Further evidence of neuropharmacologic consequences of
infection was provided by successfully treating BD rat
abnormal behaviors with the atypical neuroleptic clozapine,
ortheD1receptorantagonistSCH23390 [19],whichreduces
self-mutilation behaviors in Lesch-Nyhan patients.
Since the dopamine system is not mature in adoles-
cent rats, the changes in transmitter levels, synthetic and
catabolic enzymes, and receptor numbers described could
reﬂect direct, indirect viral eﬀects, and some of the plastic
consequences of early life viral insult. However, the most
extensive evaluation ofneurodevelopmental consequencesof
early life viral exposure has been with neonatally infected
rats. Lewis rats intracerebrally infected at birth were the ﬁrst
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4. Neonatal-InfectedRats
Borna disease of neonatally infected rats is a global neu-
rodevelopmental disorder with psychomotor abnormalities,
developmental delay, and learning diﬃculties measured by
behavioral tests of reﬂexes, stance, balance, posture, gait,
socialization, learning and play [27–29]. In neonatally-
infected animals, the development of neuropathology
roughly parallels the timecourse of microglial proliferation
and expression of MHC (major histocompatibility complex)
class I and class II, ICAM (intercellular adhesion molecule),
CD4 and CD8 molecules [30]. Inﬂammatory, survival, and
proapoptotic signals drive remodelling of the brain from
early life. Highly plastic systems, such as the monoamines
(dopamine, norepinephrine and serotinin) show changes
that include reduced serotonin transmission [31–33], an
important link to both autism and depression. The anatomic
systems that register early life reﬂexes and programs, such
as cerebellum and hippocampus, are permanently changed
[28, 32, 34–39]. In fact, in rats, early life infection by BDV
without an associated cellular inﬂammatory response in
brain, produces many of the same neuroanatomical, neu-
rochemial, neuroimmune and behavior changes recognized
in children with Autism Spectrum Disorders. Signiﬁcant
parallel changes or sequelae include a dysplastic cerebellum,
dissolution of the hippocampal dentate gyrus, early life
deﬁcits in hippocampal serotonin, and abnormalities in
domains of social (play) behavior, emotion (chronic anxi-
ety), and cognition (poor performance on spatial learning
and memory) [40].
Whether neonatally infected BD rats speciﬁcally model
viraleﬀects in utero or eﬀects on infant or child development
depends on the experimental question and which regions,
anatomic features, or behaviors are studied. For example,
the birth of the majority of granule cells of dentate gyrus of
hippocampus that takes place during ﬁrst postnatal month
in rats, occurs prenatally in man [41]. In this respect,
the gross structure of the hippocampus of a newborn rat
approximately matches a third trimester human. Therefore,
disordered macroscopic development of hippocampus, as
complex function of microglia activation [30, 42], neu-
rotrophin and cytokine signaling [28, 43–45], metabolic and
oxidative stress ([36, 37, 39], also described in adult infected
animals, [46, 47]) has direct relevance to in utero virus
exposure in man.
Alternatively, other outcome measures have relevance
for post-natal or early life consequences of CNS viral
exposure or injury. For example, synapse density in the
molecular layer of hippocampus reaches adult levels at 21
postnatal days in rat and 7–10 postnatal months in man
[41]. Structural causes of disability acquired in infancy
would be related to reductions in synaptic growth-associated
protein GAP-43, synaptophysin [48], connexin36 [49], and
binding of BDV p24 phosphoprotein to neurite growth
promoter, amphoterin/HMG-1 [50] found in neonatally
infected rats. On the other hand, hippocampal-dependent
learning and memory is established 15–16 postnatal days
in rat, 4–5 postnatal years in man [41, 51], such that
tests of learning can model consequences of viral exposure
across a broad span of childhood. Acquisition of spatial and
aversive learning, shown to be poor as neonatally infected
BD rats mature [12], was associated with increased NPY
(neuropeptide Y) expression in hippocampus [52]. Since
NPY overexpressed in hippocampus of transgenic rats is
associated with spatial learning deﬁcits [53], the results from
the BD rats are consistent with NPY upregulation being a
viralinducedneurochemicalcauseofcompromisedlearning.
The results reﬂect changes in a cognitive neurotransmitter
system that is highly plastic throughout life, contribut-
ing to our understanding of neuropeptides in childhood
learning.
5. Mice
Mice have bridged the gaps between pathogen to behavior
and genes to behavior in several important ways. Transgenic
technology has enabled studies of the role of individual
Borna proteins in disease and molecular genetic mouse
models have established mechanisms of host susceptibility
and disease outcome.
A transgenic mouse model based on astroglial expression
of the BDV phosphoprotein, had reduced BDNF (brain
derived neurotrophic factor) levels, serotonin receptor tran-
scripts and synaptic density, and behavioral abnormalities
similar to those of neonatal rat infection [54]. Transgenic
mice expressing the BDV nucleoprotein in neurons or astro-
cytes have decreased susceptibility to homotypic infection
and disease [55].
Immune determinants of Borna disease have been inves-
tigated using genetic and molecular genetic mouse models
[56]. Mice, similar to rats, could be infected with BDV by
intracerebral inoculation once natural BDV isolates were
mouse-adapted by serial passages in rat brain [57]. Most
laboratory strains of mice develop persistent infection but
remain well [57]. MRL strain mice are an exception, devel-
oping meningoencephalitic Borna disease and hyperactive,
disinhibited behaviors after adolescent infection [13]. As in
rats, severe clinical disease of mice is mediated by MHC
class I restricted cytotoxic T cells [58]. Wild type MRL mice
infected as neonates develop symptomatic disease mediated
by antiviral CD8+ T cells, in contrast to β2 microglobulin-
knock out MRL mice lacking CD8+ T cells that remain
well [58]. In another β2 microglobulin-deﬁcient strain,
C57BL/10J, also lacking CD8+ T cells, BDV-mice develop
persistent non-cytolytic infection with most neurons of
hippocampus containing viral antigen. Only mice having
hightranscriptlevelsofinterferon-gamma(IFN-γ)inducible
protein IP-10, a CXC chemokine and chemoattractant for
CXCR3+ T cells, showed poor performance on the water
maze test of spatial memory and hippocampal function [59,
60]. CNS infection without hippocampal neuronal loss or
maldevelopment distinguished neonatal mice from neonatal
rat infections, and established a role of IFN-γ on behavior
and learning when the hippocampus is apparently intact or
without structural damage by infection.
Further studies have found diﬀerences across species in
susceptibility of BDV to the antiviral action of IFN-γ. Rat
IFN-γ is less eﬃcient at blocking or reducing infection in4 Interdisciplinary Perspectives on Infectious Diseases
rat cell lines than is human IFN-γ at limiting or clearing
virus from cells of human and nonhuman primate lineage
[61].
6. Rats or Mice?
A switch to mice has never been complete. In many practical
respects, rats are superior to mice, such as subjects of com-
plex behavior or electroencephalographic studies. Biological
strategies for gene silencing, such as small interfering RNA
technology, may return some laboratories to the use of
rats.
Meanwhile, BD rats can still make contributions to
understanding gene × environment vulnerability questions
if the human genetics of a disease are known. For example,
epilepsy vulnerability has been associated with a dynorphin
promoter region polymorphism, or low dynorphin expres-
sion genotype, in man [62]. In animals, the dynorphin
system in the hippocampus is known to regulate excitability
[63]. The hypothesis that reduced dynorphin expression in
the dentate gyrus of hippocampus due to periadolescent
virus exposure leads to epileptic responses was successfully
testedwithadolescent-infectedBDrats.Epilepticeﬀectswere
associated with an absence of dynorphin from the dentate
gyrus granule cell layer, thus reproducing a neurochemical
marker of epilepsy, namely low dynorphin tone [64].
7. Conclusion
Well-chosen animal models can be powerful tools for reveal-
ing how CNS viral infection results in disrupted behavior.
The methods of behavioral research (use of photocell cages,
video tracking, operant measures, EEG and telemetry, devel-
opmental ethnograms in home cages and test situations)
were not the usual procedures and experimental vocabulary
of virus researchers. However, research in BDV has helped to
change that. Work on BDV in many labs over 2-3 decades
has illustrated the choices of subject and test procedures
that yielded important insights into pathogenesis. Work on
adolescent-infected rats has shown how infection can cause
long-term changes in emotional behavior and cognitive
capacity. Work on neonatal rats has shown how infections
during brain development can cause long-term changes
in behavior and cognitive capacity. Studies on mice have
shown infections during brain development can cause long-
term changes in these parameters in genetically vulnerable
individuals. All together, the studies have shown BDV causes
pharmacologic and lesion eﬀects in experimentally infected
species with disease outcome related to genetic background
and/or developmental maturity of nervous system at the
time of viral exposure. The same drugs that treat psy-
chiatric diseases of man treat or suppress the abnormal
behaviors of infected rodents. A next step may be to make
greater use of models based on genetic variants relevant for
neuropsychiatric disorders to study outcomes of infection.
It is anticipated that work on BD in animal models will
continue to elucidate aspects of nervous system function and
disease.
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